Note: Anecdotal reports in Russia show that Noben is pretty effective as a nootropic agent but the effect may vary depending on the individual's brain chemistry.
Country of Manufacture: Russia
Already in February 2007, Idebenon has been described as an orphan drug for the treatment of Leber's hereditary optic neuropathy (LHON). In 2016, the European commission approved the drug for the treatment of this condition. In the US, the drug has been given "fast track" by FDA as a potential treatment for Duchenne Muscular Dystrophy (DMD)
In the same time, in Russia Idebenon is being used for treatment of MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes), Leber's hereditary optic neuropathy (LHON), Duchenne muscular dystrophy (Catena) and some other conditions.
A number of researchers recommend Idebenon therapy for the treatment of various neurological disorders due its nootropic pharmacology.
Indeed, as a structural analogue of CoQ10, the drug was shown to improve cerebral blood flow and oxygen delivery to human brain. It improves metabolic processes; in particular, it increases synthesis of glucose and adenosine triphosphate (ATP) and supports lactate elimination. Also, Idebenon slows down the process of lipid peroxidation and protects membranes of neurones and mitochondria from damage.
The drug is produced by Binnopharm in a large pharmaceutical factory located in the city of Zelenograd.